Drug Trial Radar · NCT04937829
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
Jul 20, 2021
Primary completion
Nov 16, 2023
Study completion Nov 16, 2023
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults between 18 and 65 years of age who have depression (major depressive disorder). People with a current depressive episode lasting between 2 months and one and a half years can join the study. This study is for people for whom existing treatments for depression do not work sufficiently. The purpose of this study is to test how well a medicine called BI 1569912 is tolerated and whether it may help people with depression. It is planned to test 4 different dosages of BI 1569912 in this study. Each participant gets either one BI 1569912 dosage or placebo. It is decided randomly, which means by chance, who gets which treatment. Participants take BI 1569912 or placebo as tablets once during the study. Placebo tablets look like BI 1569912 tablets but do not contain any medicine. Participants also continue taking their usual medicine for depression throughout the study. Participants are in the study for about 5 weeks. During this time, they visit the study site 4 times, with a stay at the study site for 9 days. The doctors check the health of the participants and note any health problems that could have been caused by BI 1569912. The participants fill in questionnaires about their depression symptoms.
Conditions
- Depressive Disorder, Major
Interventions
5 mg BI 1569912Drug
BI 1569912Moderate-to-severe Major Depressive Disorder (MDD) patients on stable antidepressants (i.e. selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)) took a single dose of 5 milligram (mg) BI 1569912 (1 BI 1569912 5 mg tablet and 3 placebo tablets), orally in the morning.
20 mg BI 1569912Drug
Moderate-to-severe Major Depressive Disorder (MDD) patients on stable antidepressants (i.e. selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)) took a single dose of 20 milligram (mg) BI 1569912 (4 BI 1569912 5 mg tablets), taken orally in the morning.
PlaceboDrug
Moderate-to-severe Major Depressive Disorder (MDD) patients on stable antidepressants (i.e. selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI)) took four placebo tablets matching in size and weight to BI 1569912 5 mg tablets, taken orally in the morning.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Decrease From Baseline (Peak Decrease) in Montgomery-Åsberg Depression Rating Scale (MADRS) Score at Any Day Within a 7-day IntervalTime frame: Evaluations taken at baseline (day -63 to -3) and on day 1, 2, 4, 6 and 8 (with trial drug intake on day 1).
- Number of Patients With Drug-related Adverse EventsTime frame: The on treatment period + Follow up period, up to 15 days.
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Collaborative Neuroscience Network, LLC (CNS)
Garden Grove, California
Collaborative Neuroscience Research, LLC
Torrance, California
Optimus U Corporation
Miami, Florida
Research Centers of America
Oakland Park, Florida
iResearch Atlanta
Decatur, Georgia
Hassman Research Institute
Berlin, New Jersey
Hassman Research Institute
Marlton, New Jersey
Neuro-Behavioral Clinical Research
North Canton, Ohio
InSite Clinical Research
DeSoto, Texas
Pillar Clinical Research, LLC
Richardson, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.